drugset / Trial / NCT01649271
Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The aim of the study is to determine the Maximum Tolerated Dose (MTD) of afatinib in combination with 3-weekly trastuzumab in HER2 overexpressing cancer and to assess the efficacy of afatinib given at the MTD dosage, with 3-weekly trastuzumab in HER2 overexpressing metastatic breast cancer.
Timeline
- Start
- 2012-07-23
- Primary completion
- 2016-06-23
- Completion
- 2016-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | — | — |
| Subject | Trastuzumab | Monoclonal antibody | — | — |